Scancell share rise as cancer therapy trials progress – Nokturnal
Scancell shares were 10% higher in earlier trade on Monday after releasing positive news on their ModiFY trial. Scancell said their ModiFY trial had received approval from the safety review committee to expand to study after the most cohort of patients presented no safety concern and one patient displayed regression. – Advertisement – Scancell is … Read more
